Comparative Study of Safety and Efficacy of Intralesional BCG and Intralesional Vitamin D3 in Cutaneous Wart

Abstract

Background: Cutaneous warts are a common dermatological condition caused by the human papillomavirus (HPV). They are often challenging to treat due to their persistence and tendency to recur. Multiple treatment options exist, but none are universally effective, and many have limitations, such as pain, side effects, or high recurrence rates. Immunotherapy has emerged as a promising approach, utilizing agents like Bacillus Calmette Guérin (BCG) vaccine and vitamin D3 to modulate the immune response against warts. The intralesional route is particularly attractive, as it can stimulate a localized immune response, potentially improving treatment efficacy and reducing systemic side effects. This study aims to compare the efficacy and safety of intralesional BCG vaccine versus intralesional vitamin D3 in the treatment of cutaneous warts, with a focus on evaluating clinical response, adverse effects, and recurrence rates.